Minerva Neurosciences, Inc (NERV) Receives Consensus Rating of “Hold” from Brokerages
Shares of Minerva Neurosciences, Inc (NASDAQ:NERV) have earned an average rating of “Hold” from the six ratings firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $16.00.
A number of research analysts have recently commented on NERV shares. Zacks Investment Research raised Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a report on Wednesday, September 13th. Citigroup started coverage on Minerva Neurosciences in a report on Friday, September 1st. They set a “buy” rating and a $11.00 price target on the stock.
Minerva Neurosciences (NASDAQ NERV) opened at $5.70 on Friday. Minerva Neurosciences has a fifty-two week low of $4.80 and a fifty-two week high of $14.00.
A number of large investors have recently added to or reduced their stakes in the stock. Federated Investors Inc. PA grew its holdings in Minerva Neurosciences by 18.2% during the second quarter. Federated Investors Inc. PA now owns 7,535,287 shares of the biopharmaceutical company’s stock worth $66,687,000 after acquiring an additional 1,162,364 shares during the period. FMR LLC grew its holdings in Minerva Neurosciences by 13.7% during the second quarter. FMR LLC now owns 5,660,794 shares of the biopharmaceutical company’s stock worth $50,098,000 after acquiring an additional 680,000 shares during the period. Franklin Resources Inc. grew its holdings in Minerva Neurosciences by 39.0% during the second quarter. Franklin Resources Inc. now owns 1,158,100 shares of the biopharmaceutical company’s stock worth $10,249,000 after acquiring an additional 325,000 shares during the period. Vanguard Group Inc. grew its holdings in Minerva Neurosciences by 14.4% during the second quarter. Vanguard Group Inc. now owns 1,074,239 shares of the biopharmaceutical company’s stock worth $9,507,000 after acquiring an additional 134,942 shares during the period. Finally, Sphera Funds Management LTD. grew its holdings in Minerva Neurosciences by 31.9% during the third quarter. Sphera Funds Management LTD. now owns 625,000 shares of the biopharmaceutical company’s stock worth $4,750,000 after acquiring an additional 151,231 shares during the period. 73.76% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/10/minerva-neurosciences-inc-nerv-receives-consensus-rating-of-hold-from-brokerages.html.
About Minerva Neurosciences
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.